# GLP-1 Type: Technology Source: GetYourBrief — https://getyourbrief.com/entity/glp-1 Canonical HTML page: https://getyourbrief.com/entity/glp-1 ## Timeline - **2026-07-21**: Lawsuit filed — Novo Nordisk sues Eli Lilly in federal court, alleging misleading advertising. - **2026-04**: Cease-and-desist letter — Novo Nordisk sends a formal request to Eli Lilly to stop running or correct certain ads. - **2026-03**: Settlement Reached — Hims & Hers agrees to stop selling compounded GLP-1s to resolve legal disputes. - **2026-03**: High-dose Wegovy approved — Novo Nordisk’s high-dose obesity injection enters the market, achieving weight loss more comparable to Zepbound. - **2026-01-01**: Payer Agreement Shift — New payer contracts take effect, shifting GTN expectations to the high 30% range for the fiscal year. - **2025-12-31**: Q4 Milestone — Patient count surpasses 36,000 and quarterly revenue exceeds $320 million. - **2025-12-31**: Patent Extension — Secured Rezdiffra patent protection through 2045. - **2025-11-20**: DGAT-2 and siRNA Expansion — Acquired late-stage DGAT-2 inhibitor and six preclinical siRNA assets. - **2025-09-30**: GLP-1 Strategic Acquisition — Madrigal makes a $120 million upfront payment for an oral GLP-1 asset to expand its metabolic pipeline. - **2025-09-15**: GLP-1 Acquisition — Madrigal paid $120 million upfront to acquire an oral GLP-1 program. - **2025-03-01**: Rezdiffra Commercial Launch — First full year of Rezdiffra availability in the U.S. market for MASH. - **2025-01-01**: Rezdiffra Full-Year Launch — Madrigal begins its first full year of commercial sales for the first-ever approved MASH treatment. - **2025**: Litigation Surge — Novo Nordisk and Eli Lilly file multiple lawsuits against compounding pharmacies and telehealth firms. - **2024**: FDA Shortage Updates — FDA begins removing specific GLP-1 dosages from the national shortage list. - **2024-05**: HIMS Launches GLP-1s — Hims & Hers enters the weight-loss market with compounded GLP-1 offerings. ## Recent coverage (10 stories, network-wide) ### Pharma's Obesity Boom: Novo Nordisk's 70% Volume Surge Raises Energy Footprint Questions 2026-08-10 22:52:11 · Sector: climate · Sentiment: Neutral · Impact: 6/10 · Sources: 2 Novo Nordisk’s soaring obesity drug volumes—up 70% year-over-year—signal escalating demand for energy-intensive pharmaceutical manufacturing. While expanding access to GLP-1 therapies may reduce long-term healthcare burdens, the immediate production ramp-up presents sustainability challenges that the pharma sector must address. Full story: https://getclimatebrief.com/story/novo-nordisk-obesity-manufacturing-energy-climate ### Wegovy Pill at 267K Weekly Scripts, 90% of U.S. Oral Obesity Market—Novo Nordisk Q2 2026-08-10 22:51:34 · Sector: bio · Sentiment: Neutral · Impact: 6/10 · Sources: 2 Novo Nordisk’s Q2 earnings reveal explosive uptake of its oral Wegovy pill, now commanding 90% of the U.S. oral obesity market with 267,000 weekly scripts. The therapy is expanding the GLP-1 market, with 80% of users being treatment-naïve, signaling a new era in obesity pharmacotherapy. Full story: https://getbiobrief.com/story/novo-nordisk-q2-wegovy-pill-obesity-boom-bio ### Novo Nordisk sues Eli Lilly under Lanham Act over 2-year-old GLP-1 ad claims 2026-07-21 22:05:06 · Sector: legal · Sentiment: Negative · Impact: 7/10 · Sources: 2 Novo Nordisk alleges Eli Lilly’s comparative advertising for Zepbound relies on outdated clinical data, violating the Lanham Act. The case could redefine how quickly pharma competitors must update ad claims when new drug formulations enter the market. Full story: https://getlegalbrief.com/story/novo-sues-lilly-misleading-glp1-ads-lanham-act ### FDA Issues Warning to Novo Nordisk Over GLP-1 Adverse Event Reporting 2026-03-12 23:24:58 · Sector: health · Sentiment: Negative · Impact: 7/10 · Sources: 3 The FDA has issued a formal warning letter to Novo Nordisk for failing to properly report serious adverse events, including deaths and strokes, related to its GLP-1 medications. This regulatory escalation coincides with a significant market valuation decline and intensifying competition from compounding pharmacies. Full story: https://gethealthbrief.com/story/fda-warning-novo-nordisk-glp1-reporting-failures ### Hims & Hers to Halt Compounded GLP-1 Sales Following Legal Settlement 2026-03-09 17:34:05 · Sector: health · Sentiment: Negative · Impact: 6/10 · Sources: 2 Hims & Hers Health has agreed to cease the sale of compounded GLP-1 medications as part of a legal settlement, marking a significant shift in its weight-loss business strategy. This move follows mounting pressure from pharmaceutical manufacturers and highlights the tightening regulatory environment for telehealth platforms leveraging drug shortages. Full story: https://gethealthbrief.com/story/hims-hers-settles-glp1-lawsuit-compounding ### Hims & Hers Health to Halt Compounded GLP-1 Sales in Landmark Settlement 2026-03-09 17:30:26 · Sector: legal · Sentiment: Negative · Impact: 6/10 · Sources: 2 Hims & Hers Health has agreed to cease the sale of compounded GLP-1 medications as part of a legal settlement, marking a significant shift in the telehealth landscape. This move follows intense regulatory scrutiny and litigation regarding the legality of compounding patented weight-loss drugs during supply shortages. Full story: https://getlegalbrief.com/story/hims-hers-glp1-settlement-regulation ### Agilent Q1 2026: Pharma Resilience Battles Academic Funding Headwinds 2026-02-26 00:37:40 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2 Agilent reported a 4.4% core revenue growth in Q1 2026, driven by a strong 7% uptick in the pharmaceutical sector despite an 8% decline in academic and government markets. The company is navigating margin pressures from new tariffs while leaning into high-growth areas like GLP-1 manufacturing and CDMO services. Full story: https://getbiobrief.com/story/agilent-q1-2026-earnings-pharma-vs-academia ### Agilent Navigates Tariff Headwinds and Academic Softness in Q1 2026 2026-02-26 00:37:03 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2 Agilent Technologies reported a resilient Q1 2026 with $1.8 billion in revenue, driven by a 7% growth in the pharma sector despite significant headwinds in academic and government funding. While the company faced a 100-basis-point gross margin compression due to rising tariffs and weather disruptions, strong performance in the Agilent CrossLab Group suggests a shift toward service-oriented recurring revenue. Full story: https://gethealthbrief.com/story/agilent-q1-2026-earnings-analysis-healthcare-it ### Madrigal’s Rezdiffra Surpasses $950M in 2025 as Pipeline Expands into GLP-1s 2026-02-24 00:14:25 · Sector: bio · Sentiment: Positive · Impact: 7/10 · Sources: 5 Madrigal Pharmaceuticals reported a transformative 2025, with Rezdiffra net sales reaching $958.4 million during its first full year on the market. The company is aggressively pivoting toward a multi-asset metabolic powerhouse, integrating oral GLP-1 and DGAT-2 programs alongside its core MASH franchise. Full story: https://getbiobrief.com/story/madrigal-pharma-q4-2025-earnings-rezdiffra-growth ### Madrigal Pharmaceuticals Triples Q4 Revenue as Rezdiffra Adoption Accelerates 2026-02-24 00:09:59 · Sector: health · Sentiment: Positive · Impact: 7/10 · Sources: 5 Madrigal Pharmaceuticals reported a transformative Q4 2025, with Rezdiffra net sales reaching $321.1 million and a patient base exceeding 36,000. The company is aggressively expanding its metabolic pipeline, integrating GLP-1 and siRNA technologies to solidify its leadership in the MASH market. Full story: https://gethealthbrief.com/story/madrigal-q4-2025-earnings-rezdiffra-mash-market --- This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.